Q-omics provides the consensus-scored MIR5685 profile across patient tissues and cancer cell-line models. MIR5685 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIR5685 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, MIR5685 RNA expression shows 15,404 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BRCA, KICH, and DLBC as cancer lineages where MIR5685 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5685 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5685 survival associations across molecular data types. MIR5685 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5685 RNA expression–survival associations across cancer types. High MIR5685 expression shows unfavorable associations in THCA, KIRP and UVM, but favorable associations in BRCA, LUAD and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MIR5685 RNA expression.
This table summarizes MIR5685 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5685. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5685 shows lower tumor expression in KICH, LUAD, THCA and LUSC and higher tumor expression in KIRC and PRAD. The KICH box plot shows higher MIR5685 RNA expression in normal versus tumor tissue (log2 FC = −0.890, t-test p < 0.001).
This table shows molecular features associated with MIR5685 in patient tissues and cancer cell lines. In patient samples, MIR5685 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
